B. Scott Ullem's most recent trade in Illumina Inc was a trade of 167 Common Stock done at an average price of $149.2 . Disclosure was reported to the exchange on June 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 149.19 per share. | 30 Jun 2026 | 167 | 11,030 (0%) | 0% | 149.2 | 24,914 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 144.83 per share. | 21 May 2026 | 2,072 | 10,863 (0%) | 0% | 144.8 | 300,088 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 19,830 | 57,744 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 19,830 | 0 | - | - | Performance Rights | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.96 per share. | 11 May 2026 | 11,004 | 46,740 (0%) | 0% | 80.0 | 879,880 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.76 per share. | 07 May 2026 | 1,661 | 37,914 (0%) | 0% | 82.8 | 137,464 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.20 per share. | 07 May 2026 | 1,373 | 39,575 (0%) | 0% | 83.2 | 114,234 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 59.26 per share. | 03 May 2026 | 13,000 | 52,079 (0%) | 0% | 59.3 | 770,337 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2026 | 13,000 | 0 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.91 per share. | 03 May 2026 | 11,131 | 40,948 (0%) | 0% | 82.9 | 922,871 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.98 per share. | 03 May 2026 | 620 | 39,079 (0%) | 0% | 84.0 | 52,068 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 59.26 per share. | 09 Apr 2026 | 13,000 | 52,699 (0%) | 0% | 59.3 | 770,337 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2026 | 13,000 | 13,000 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 79.79 per share. | 09 Apr 2026 | 8,324 | 39,699 (0%) | 0% | 79.8 | 664,144 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 80.50 per share. | 09 Apr 2026 | 4,676 | 48,023 (0%) | 0% | 80.5 | 376,401 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 131.55 per share. | 31 Mar 2026 | 190 | 8,791 (0%) | 0% | 131.5 | 24,994 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 59.26 per share. | 11 Mar 2026 | 13,000 | 52,699 (0%) | 0% | 59.3 | 770,337 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2026 | 13,000 | 26,000 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 85.21 per share. | 11 Mar 2026 | 7,901 | 39,699 (0%) | 0% | 85.2 | 673,228 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 84.46 per share. | 11 Mar 2026 | 5,099 | 47,600 (0%) | 0% | 84.5 | 430,668 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 117.63 per share. | 31 Dec 2025 | 212 | 8,601 (0%) | 0% | 117.6 | 24,938 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 09 Dec 2025 | 7,700 | 39,000 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 09 Dec 2025 | 7,700 | 39,898 (0%) | 0% | 84.5 | 650,412 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 09 Dec 2025 | 7,700 | 47,598 (0%) | 0% | 59.3 | 456,277 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 10 Nov 2025 | 13,000 | 52,898 (0%) | 0% | 59.3 | 770,337 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 10 Nov 2025 | 13,000 | 46,700 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 10 Nov 2025 | 10,026 | 39,898 (0%) | 0% | 83.0 | 832,360 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 10 Nov 2025 | 2,974 | 49,924 (0%) | 0% | 83.3 | 247,734 | Common Stock | |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 99.17 per share. | 30 Sep 2025 | 252 | 8,389 (0%) | 0% | 99.2 | 24,990 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 81.20 per share. | 30 Jun 2025 | 307 | 8,137 (0%) | 0% | 81.2 | 24,928 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 3,780 | 7,830 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Scott B. Ullem | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.62 per share. | 16 May 2025 | 1,070 | 4,050 (0%) | 0% | 83.6 | 89,473 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 11 May 2025 | 1,200 | 39,898 (0%) | 0% | 73.7 | 88,416 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 07 May 2025 | 75,200 | 75,200 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 07 May 2025 | 13,400 | 13,400 | - | - | Performance Rights | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 07 May 2025 | 13,400 | 41,098 (0%) | 0% | 0 | Common Stock | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 07 May 2025 | 11,250 | 0 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 07 May 2025 | 11,250 | 41,098 (0%) | 0% | 74.4 | 837,035 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 07 May 2025 | 11,250 | 52,348 (0%) | 0% | 45.3 | 509,363 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 07 May 2025 | 1,406 | 27,698 (0%) | 0% | 74.9 | 105,338 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 03 May 2025 | 648 | 29,104 (0%) | 0% | 75.6 | 49,021 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 03 May 2025 | 635 | 29,752 (0%) | 0% | 75.7 | 48,038 | Common Stock | |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 104.92 per share. | 31 Mar 2025 | 229 | 5,120 (0%) | 0% | 104.9 | 24,027 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 26 Mar 2025 | 11,250 | 11,250 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 26 Mar 2025 | 11,250 | 30,387 (0%) | 0% | 70.9 | 797,267 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 26 Mar 2025 | 11,250 | 41,637 (0%) | 0% | 45.3 | 509,363 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 28 Feb 2025 | 11,250 | 22,500 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 28 Feb 2025 | 11,250 | 41,637 (0%) | 0% | 45.3 | 509,363 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 28 Feb 2025 | 7,760 | 30,387 (0%) | 0% | 70.5 | 547,204 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 28 Feb 2025 | 3,490 | 38,147 (0%) | 0% | 71.4 | 249,123 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 16 Feb 2025 | 174 | 30,387 (0%) | 0% | 76.2 | 13,257 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 13 Feb 2025 | 11,250 | 30,561 (0%) | 0% | 75.8 | 852,272 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 13 Feb 2025 | 11,250 | 41,811 (0%) | 0% | 45.3 | 509,363 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 13 Feb 2025 | 11,250 | 33,750 | - | - | Employee Stock Option (Right to Acquire) | ||
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 142.06 per share. | 31 Dec 2024 | 158 | 4,891 (0%) | 0% | 142.1 | 22,446 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 09 Dec 2024 | 11,250 | 41,811 (0%) | 0% | 45.3 | 509,363 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 09 Dec 2024 | 11,250 | 45,000 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 09 Dec 2024 | 11,250 | 30,561 (0%) | 0% | 71.7 | 806,406 | Common Stock | |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 122.78 per share. | 30 Sep 2024 | 183 | 4,733 (0%) | 0% | 122.8 | 22,469 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 109.65 per share. | 28 Jun 2024 | 205 | 4,550 (0%) | 0% | 109.7 | 22,479 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 20 Jun 2024 | 5,625 | 36,186 (0%) | 0% | 45.3 | 254,681 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 20 Jun 2024 | 5,625 | 56,250 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 20 Jun 2024 | 5,225 | 30,561 (0%) | 0% | 87.5 | 457,013 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 20 Jun 2024 | 400 | 35,786 (0%) | 0% | 88.1 | 35,245 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 21 May 2024 | 5,625 | 30,561 (0%) | 0% | 90.5 | 508,803 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 21 May 2024 | 5,625 | 61,875 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 21 May 2024 | 5,625 | 36,186 (0%) | 0% | 45.3 | 254,681 | Common Stock | |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,622 | 4,292 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 11 May 2024 | 1,198 | 30,561 (0%) | 0% | 86.7 | 103,891 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 07 May 2024 | 65,500 | 65,500 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 07 May 2024 | 11,075 | 32,549 (0%) | 0% | 0 | Common Stock | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 07 May 2024 | 11,075 | 11,075 | - | - | Performance Rights | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 07 May 2024 | 790 | 31,759 (0%) | 0% | 85.1 | 67,221 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 03 May 2024 | 7,465 | 25,905 (0%) | 0% | 0 | Common Stock | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 03 May 2024 | 7,465 | 0 | - | - | Performance Rights | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 03 May 2024 | 4,431 | 21,474 (0%) | 0% | 85.3 | 377,743 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 03 May 2024 | 634 | 18,440 (0%) | 0% | 85.1 | 53,928 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 30 Apr 2024 | 7,250 | 26,324 (0%) | 0% | 36.8 | 266,438 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 30 Apr 2024 | 7,250 | 0 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 30 Apr 2024 | 6,550 | 19,074 (0%) | 0% | 85.7 | 561,579 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 30 Apr 2024 | 700 | 25,624 (0%) | 0% | 86.4 | 60,483 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 01 Apr 2024 | 7,255 | 26,329 (0%) | 0% | 36.7 | 266,621 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 01 Apr 2024 | 7,255 | 7,250 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 01 Apr 2024 | 6,387 | 19,074 (0%) | 0% | 94.8 | 605,521 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 01 Apr 2024 | 868 | 25,461 (0%) | 0% | 95.5 | 82,903 | Common Stock | |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 137.68 per share. | 28 Mar 2024 | 163 | 1,670 (0%) | 0% | 137.7 | 22,442 | Common Stock |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 29 Feb 2024 | 7,255 | 14,505 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | B. Scott Ullem | CVP, Chief Financial Officer | 29 Feb 2024 | 7,255 | 19,074 (0%) | 0% | 85.6 | 620,923 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 29 Feb 2024 | 7,255 | 26,329 (0%) | 0% | 36.7 | 266,621 | Common Stock | |
| Edwards Lifesciences | Ullem B. Scott | CVP, Chief Financial Officer | 16 Feb 2024 | 174 | 19,074 (0%) | 0% | 86.0 | 14,971 | Common Stock | |
| Edwards Lifesciences | B. Ullem Scott | CVP, Chief Financial Officer | 01 Feb 2024 | 7,255 | 26,503 (0%) | 0% | 36.7 | 266,621 | Common Stock | |
| Edwards Lifesciences | Ullem B. Scott | CVP, Chief Financial Officer | 01 Feb 2024 | 7,255 | 21,760 | - | - | Employee Stock Option (Right to Acquire) | ||
| Edwards Lifesciences | Scott Ullem B. | CVP, Chief Financial Officer | 01 Feb 2024 | 7,255 | 19,248 (0%) | 0% | 78.3 | 567,994 | Common Stock | |
| Edwards Lifesciences | B. Ullem Scott | CVP, Chief Financial Officer | 29 Dec 2023 | 14,510 | 33,758 (0%) | 0% | 36.8 | 533,243 | Common Stock | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 29 Dec 2023 | 14,510 | 19,248 (0%) | 0% | 76.6 | 1,110,794 | Common Stock | |
| Edwards Lifesciences | Ullem Scott B. | CVP, Chief Financial Officer | 29 Dec 2023 | 14,510 | 29,015 | - | - | Employee Stock Option (Right to Acquire) | ||
| Berry Global Group Inc | Scott B. Ullem | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2023 | 1,970 | 1,393 | - | - | Restricted Stock Units | |
| Berry Global Group Inc | Scott B. Ullem | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2023 | 1,970 | 4,728 (0%) | 0% | - | Common Stock | |
| Berry Global Group Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2023 | 2,823 | 57,235 | - | - | Director Stock Option (Right to Buy) | |
| Berry Global Group Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2023 | 1,393 | 3,363 | - | - | Restricted Stock Units | |
| Edwards Lifesciences | Scott B. Ullem | CVP, Chief Financial Officer | 31 Oct 2023 | 7,255 | 43,525 | - | - | Employee Stock Option (Right to Acquire) |